Abiopharma

🔍 Bradley Alexander R. (Executive)

Company: FIRST SOLAR, INC. (FSLR)

Report Date: 2026-03-13

Detailed Transactions and Holdings:

• Acquired 1,441 shares of Common Stock (Direct)
  Date: 2026-03-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 44,696.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 590 shares of Common Stock at $200.8 per share (Direct)
  Date: 2026-03-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 44,106.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,958 shares of Common Stock at $198.8 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 41,148.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 5,376 shares of Common Stock at $199.75 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 35,772.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 5,075 shares of Common Stock at $200.59 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,697.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 346 shares of Common Stock at $201.65 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,351.00 | transaction_form_type: 4 | Footnotes: F3, F7
• Sold 351 shares of Common Stock at $202.44 per share (Direct)
  Date: 2026-03-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F3, F8
• Sold 1,441 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,440.00 | transaction_form_type: 4 | Footnotes: F9, F10, F10

Footnotes:

• F1: Represents shares of common stock issued upon vesting of 20% of the restricted stock units granted on March 15, 2022.
• F2: Represents shares of common stock sold by the Issuer to satisfy certain tax withholding obligations with the vesting of the restricted stock units.
• F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person on November 6, 2025.
• F4: This transaction was executed in multiple trades at prices ranging from $198.23 to $199.22 The price reported above reflects the weighted average sale price for the transactions reported on this line. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: This transaction was executed in multiple trades at prices ranging from $199.23 to $200.22 The price reported above reflects the weighted average sale price for the transactions reported on this line. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: This transaction was executed in multiple trades at prices ranging from $200.23 to $201.17. The price reported above reflects the weighted average sale price for the transactions reported on this line. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: This transaction was executed in multiple trades at prices ranging from $201.23 to $202.21. The price reported above reflects the weighted average sale price for the transactions reported on this line. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F8: This transaction was executed in multiple trades at prices ranging from $202.32 to $202.55. The price reported above reflects the weighted average sale price for the transactions reported on this line. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F9: Each restricted stock unit represents the right to receive, upon vesting, one share of the Issuer's common stock in accordance with the Issuer's 2020 Omnibus Incentive Compensation Plan.
• F10: The restricted stock units were granted on March 15, 2022 as part of the Issuer's annual equity grant to executive officers. The restricted stock units granted on March 15, 2022 are scheduled to vest annually at a rate of 20% on each anniversary of the grant date, commencing on the first anniversary of the grant date.